CleanCap® Reagent M6 [CleanCap m6AG (3’ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNAs produced by legacy capping methods. The addition of a methyl group on position 6 of the first adenosine (m6A) may further increase protein expression relative to CleanCap AG or CleanCap AG (3’OMe). It has been hypothesized that the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)​ CleanCap M6 uses the same 5’ AG initiation sequence as CleanCap AG and CleanCap AG (3’OMe). ​ CleanCap has been shown to provide > 95% capping efficiency and typical crude yields of 4 mg to 5 mg per mL of transcription.​ CleanCap M6 can be used in conjunction with wildtype bases or TriLink’s catalog of modified NTPs, such as N1-Methylpseudouridine-5’-Triphosphate (N-1081), Pseudouridine-5’-Tr

CleanCap® Reagent M6 [CleanCap m6AG (3’ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNAs produced by legacy capping methods. The addition of a methyl group on position 6 of the first adenosine (m6A) may further increase protein expression relative to CleanCap AG or CleanCap AG (3’OMe). It has been hypothesized that the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)​ CleanCap M6 uses the same 5’ AG initiation sequence as CleanCap AG and CleanCap AG (3’OMe). ​ CleanCap has been shown to provide > 95% capping efficiency and typical crude yields of 4 mg to 5 mg per mL of transcription.​ CleanCap M6 can be used in conjunction with wildtype bases or TriLink’s catalog of modified NTPs, such as N1-Methylpseudouridine-5’-Triphosphate (N-1081), Pseudouridine-5’-Tr

CleanCap® Reagent M6 [CleanCap m6AG (3’ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNAs produced by legacy capping methods. The addition of a methyl group on position 6 of the first adenosine (m6A) may further increase protein expression relative to CleanCap AG or CleanCap AG (3’OMe). It has been hypothesized that the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)​ CleanCap M6 uses the same 5’ AG initiation sequence as CleanCap AG and CleanCap AG (3’OMe). ​ CleanCap has been shown to provide > 95% capping efficiency and typical crude yields of 4 mg to 5 mg per mL of transcription.​ CleanCap M6 can be used in conjunction with wildtype bases or TriLink’s catalog of modified NTPs, such as N1-Methylpseudouridine-5’-Triphosphate (N-1081), Pseudouridine-5’-Tr

Ribonucleoside triphosphates (rNTPs) are the building blocks of RNA molecules and are essential to the success of RNA drug development. TriLink’s rNTPs are manufactured under stringent quality standards in an ISO-9001 certified facility, offering exceptional quality, purity, and consistency. They are ideally suited for RNA synthesis in research, diagnostics, therapeutics, and vaccine development. Substituting uridines with modified uridines, such as N1-methylpseudouridine, 5-methoxyuridine, and pseudouridine, can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression. The rNTP set with N1-methylpseudo-UTP contains separate tubes of 100 mM ATP, CTP, GTP, and N1MePs-UTP in H2O, pH 7.5. The rNTPs can be used with TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.

Ribonucleoside triphosphates (rNTPs) are the building blocks of RNA molecules and are essential to the success of RNA drug development. TriLink’s rNTPs are manufactured under stringent quality standards in an ISO-9001 certified facility, offering exceptional quality, purity, and consistency. They are ideally suited for RNA synthesis in research, diagnostics, therapeutics, and vaccine development. Substituting uridines with modified uridines, such as N1-methylpseudouridine, 5-methoxyuridine, and pseudouridine, can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression. The rNTP set with 5-methoxy-UTP contains separate tubes of 100 mM ATP, CTP, GTP, and 5mo-UTP in H2O, pH 7.5. The rNTPs can be used with TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.

Ribonucleoside triphosphates (rNTPs) are the building blocks of RNA molecules and are essential to the success of RNA drug development. TriLink’s rNTPs are manufactured under stringent quality standards in an ISO-9001 certified facility, offering exceptional quality, purity, and consistency. They are ideally suited for RNA synthesis in research, diagnostics, therapeutics, and vaccine development. Substituting uridines with modified uridines, such as N1-methylpseudouridine, 5-methoxyuridine, and pseudouridine, can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression. The rNTP set with pseudo-UTP contains separate tubes of 100 mM ATP, CTP, GTP, and pseudo-UTP in H2O, pH 7.5. The rNTPs can be used with TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.

Wild-type bacteriophage T7 RNA polymerase is a highly processive, 100 kDa, DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene regulated by the T7 promoter. It is a key enzyme used to synthesize mRNA (messenger RNA) from a DNA template. It is highly efficient and specific, capable of transcribing large quantities of RNA in a relatively short time frame. Its high robustness and reproducibility makes it the standard industry choice for mRNA synthesis as well as other applications such as saRNA synthesis, radiolabeled RNA probe preparation, and RNA construct development for additional studies. The provided pack sizes are configured to run 25 rxns or 250 rxns of 100-μL IVT, following our recommended co-transcriptional protocol to produce Cap-1 mRNAs. Please see the details in the product insert.The 100 µg and 840 µg pack sizes contain approximately 50,000 units and 420,000 units of enzymes, respectively.  Unit definition: One unit of enzy

Wild-type bacteriophage T7 RNA polymerase is a highly processive, 100 kDa, DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene regulated by the T7 promoter. It is a key enzyme used to synthesize mRNA (messenger RNA) from a DNA template. It is highly efficient and specific, capable of transcribing large quantities of RNA in a relatively short time frame. Its high robustness and reproducibility makes it the standard industry choice for mRNA synthesis as well as other applications such as saRNA synthesis, radiolabeled RNA probe preparation, and RNA construct development for additional studies. The provided pack sizes are configured to run 25 rxns or 250 rxns of 100-μL IVT, following our recommended co-transcriptional protocol to produce Cap-1 mRNAs. Please see the details in the product insert.The 100 µg and 840 µg pack sizes contain approximately 50,000 units and 420,000 units of enzymes, respectively.  Unit definition: One unit of enzy

E. coli inorganic pyrophosphatase (iPPase) catalyzes the hydrolysis of inorganic pyrophosphate (PPi) to form orthophosphate. Using iPPase in an in vitro transcription reaction drives RNA synthesis forward by removing pyrophosphate which forms as a byproduct and precipitates with key transcription buffer cations. The provided pack sizes are configured to run 25 rxns or 250 rxns of 100-μL IVT, following our recommended co-transcriptional protocol to produce Cap-1 mRNAs. Please see the details in the product insert. The 30 µg and 310 µg pack sizes contain approximately 6 units and 62 units of enzymes, respectively. Unit definition: One unit of enzyme produces 1 µmol of phosphate from inorganic pyrophosphate in 1 min at 25°C.

E. coli inorganic pyrophosphatase (iPPase) catalyzes the hydrolysis of inorganic pyrophosphate (PPi) to form orthophosphate. Using iPPase in an in vitro transcription reaction drives RNA synthesis forward by removing pyrophosphate which forms as a byproduct and precipitates with key transcription buffer cations. The provided pack sizes are configured to run 25 rxns or 250 rxns of 100-μL IVT, following our recommended co-transcriptional protocol to produce Cap-1 mRNAs. Please see the details in the product insert. The 30 µg and 310 µg pack sizes contain approximately 6 units and 62 units of enzymes, respectively. Unit definition: One unit of enzyme produces 1 µmol of phosphate from inorganic pyrophosphate in 1 min at 25°C.